OBSV News and Press, ObsEva SA From 09/03/20

  GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reprod...

EyeGate Pharmaceuticals (NASDAQ: EYEG ) +35%  on development path for conjunctivitis treatment. More news on: EyeGate Pharmaceuticals, Inc., Cellular Biomedicine Group, Inc., Vascular Biogenics Ltd., Stocks on the move, , Read more ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

  Geneva, Switzerland and Boston, MA –  August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye wil...

ObsEva (NASDAQ: OBSV ) : Q2 GAAP EPS of -$0.38 beats by $0.04 . More news on: ObsEva SA, Earnings news and commentary, Healthcare stocks news, , Read more ...

  Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids Phase 3 data from PRIMROSE 2 trial demonstrated sustained efficacy and continued safety over 52 weeks of treatment with li...

  Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced winning the Clinical Science Award...

ObsEva Reports Positive Data from Phase 3 Uterine Fibroids Studies ObsEva SA ( OBSV ) announced positive top line data from its PRIMROSE 1 and 2 studies. PRIMROSE 1 met its primary endpoint at week 24 while PRIMROSE 2 data showed that continued treatment with linzagolix for 52 weeks offe...

Corvus Pharmaceuticals (NASDAQ: CRVS ) +103%  on launch immunotherapy study for COVID-19. More news on: Corvus Pharmaceuticals, Inc., Annovis Bio, Inc., Novavax, Inc., Stocks on the move, , Read more ...

Gainers:  Ayro (NASDAQ: AYRO )  +102% . More news on: Ayro, Inc., Electrameccanica Vehicles Corp., LM Funding America, Inc., Stocks on the move, , Read more ...